ARJO-B Stock Analysis: Arjo (publ) | ST

Total Rating 37

Safety 86

Buy Signal 1.00

Medical Distribution
Industry Rotation: +18.3

Market Cap: 890M
Avg Turnover: 8.40M

Risk 3d forecast

Volatility60.8%

VaR 5^th Pctl9.15%

VaR vs Median-7.55%

Reward TTM

Sharpe Ratio0.23

Rel. Str. IBD80

Rel. Str. Peer Group51.5 pctl

Character TTM

Beta0.385

Beta Downside0.244

Hurst Exponent0.467

Choppyness66.5%

Drawdowns 3y

Max DD51.27%

CAGR/Max DD-0.01

CAGR/Mean DD-0.02

EPS (Earnings per Share)

EPS CAGR: -10.28%
EPS Trend: -79.0%

Last SUE: -0.73
Qual. Beats: 0

Revenue

Rev. CAGR: -0.06%
Rev. Trend: -3.3%

Last SUE: 0.71
Qual. Beats: 0

Warnings

Overextended 3d

Tailwinds

Idiosyncratic Leader

Ep Pivot

Seasonality

Not enough history

Description: ARJO-B Arjo (publ)

Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, hygiene, prevention of pressure injuries and blood clots, and leg ulcer treatment and prevention, as well as for obstetric and cardiac diagnostics. The company also provides dementia care, bariatric room solutions, prone positioning, early mobility, architects and planners, and rehabilitation services, as well as equipment repair and maintenance, and equipment rental and financing solutions. It serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden.

Headlines to Watch Out For

Piotroski VR-10 (Strict) 3.5

Net Income: 384.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.50 > 1.0
NWC/Revenue: 17.53% < 20% (prev 8.63%; Δ 8.90% < -1%)
CFO/TA 0.10 > 3% & CFO 1.54b > Net Income 384.0m
Net Debt (6.05b) to EBITDA (1.78b): 3.40 < 3
Current Ratio: 1.73 > 1.5 & < 3
Outstanding Shares: last quarter (272.4m) vs 12m ago -0.00% < -2%
Gross Margin: 38.59% > 18% (prev 43.46%; Δ -4.87% > 0.5%)
Asset Turnover: 70.12% > 50% (prev 72.86%; Δ -2.74% > 0%)
Interest Coverage Ratio: 3.16 > 6 (EBIT TTM 654.0m / Interest Expense TTM 207.0m)

Altman Z'' 3.47

A: 0.12 (Total Current Assets 4.54b - Total Current Liabilities 2.63b) / Total Assets 15.7b
B: 0.42 (Retained Earnings 6.53b / Total Assets 15.7b)
C: 0.04 (EBIT TTM 654.0m / Avg Total Assets 15.6b)
D: 0.98 (Book Value of Equity 7.76b / Total Liabilities 7.92b)
Altman-Z'' = 3.47 = A

Beneish M -2.88

DSRI: 1.07 (Receivables 2.41b/2.33b, Revenue 10.9b/11.3b)
GMI: 1.13 (GM 43.46% / 38.59%)
AQI: 1.01 (AQ_t 0.53 / AQ_t-1 0.53)
SGI: 0.97 (Revenue 10.9b / 11.3b)
TATA: -0.07 (NI 384.0m - CFO 1.54b) / TA 15.7b)
Beneish M = -2.88 (Cap -4..+1) = A

What is the price of ARJO-B shares?

As of October 23, 2026, the stock is trading at SEK 32.32 with a total of 2,992,278 shares traded. Over the past week, the price has changed by +14.69%, over one month by +11.83%, over three months by +21.87% and over the past year by +9.58%.

Current recommended Stop Loss: 31.60 (which is 2.2% or 1.2 ATR below the current price).

Is ARJO-B a buy, sell or hold?

Arjo (publ) has no consensus analysts rating.

Arjo (publ) (ARJO-B) - Fundamental Data Overview as of 23 October 2026

Market Cap USD = 890.0m (8.80b SEK * 0.1011 SEK.USD)
P/E Trailing = 22.7606
P/E Forward = 13.7931
P/S = 0.8064
P/B = 1.0118
Revenue TTM = 10.9b SEK
EBIT TTM = 654.0m SEK
EBITDA TTM = 1.78b SEK
Long Term Debt = 2.64b SEK (from longTermDebt, last fiscal year)
Short Term Debt = 2.04b SEK (from shortTermDebt, last quarter)
Debt = 6.87b SEK (from shortLongTermDebtTotal, last quarter) + Leases 1.29b
Net Debt = 6.05b SEK (calculated: Debt 6.87b - CCE 818.0m)
Enterprise Value = 14.9b SEK (8.80b + Debt 6.87b - CCE 818.0m)
Interest Coverage Ratio = 3.16 (Ebit TTM 654.0m / Interest Expense TTM 207.0m)
EV/FCF = 15.39x (Enterprise Value 14.9b / FCF TTM 965.0m)
FCF Yield = 6.50% (FCF TTM 965.0m / Enterprise Value 14.9b)
FCF Margin = 8.84% (FCF TTM 965.0m / Revenue TTM 10.9b)
Net Margin = 3.52% (Net Income TTM 384.0m / Revenue TTM 10.9b)
Gross Margin = 38.59% ((Revenue TTM 10.9b - Cost of Revenue TTM 6.70b) / Revenue TTM)
Gross Margin QoQ = 38.78% (prev 39.21%)
Tobins Q-Ratio = 0.95 (Enterprise Value 14.9b / Total Assets 15.7b)
Interest Expense / Debt = 3.01% (Interest Expense 207.0m / Debt 6.87b)
Taxrate = 28.09% (150.0m / 534.0m)
NOPAT = 470.3m (EBIT 654.0m * (1 - 28.09%))
Current Ratio = 1.73 (Total Current Assets 4.54b / Total Current Liabilities 2.63b)
Debt / Equity = 0.89 (Debt 6.87b / totalStockholderEquity, last quarter 7.76b)
Debt / EBITDA = 3.40 (Net Debt 6.05b / EBITDA 1.78b)
Debt / FCF = 6.27 (Net Debt 6.05b / FCF TTM 965.0m)
Total Stockholder Equity = 7.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.47% (Net Income 384.0m / Total Assets 15.7b)
RoE = 5.03% (Net Income TTM 384.0m / Total Stockholder Equity 7.64b)
RoCE = 6.37% (EBIT 654.0m / Capital Employed (Equity 7.64b + L.T.Debt 2.64b))
RoIC = 3.23% (NOPAT 470.3m / Invested Capital 14.5b)
WACC = 4.85% (E(8.80b)/V(15.7b) * Re(6.94%) + D(6.87b)/V(15.7b) * Rd(3.01%) * (1-Tc(0.28)))
Discount Rate = 6.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.64 | Cagr: -0.00%
[DCF] Terminal Value 74.55% ; FCFF base≈990.6m ; Y1≈942.9m ; Y5≈897.4m
[DCF] Fair Price = 31.77 (EV 14.1b - Net Debt 6.05b = Equity 8.07b / Shares 254.2m; r=8.35% [WACC [floored]]; 5y FCF grow -6.22% → 2.50% )
EPS Correlation: -79.04 | EPS CAGR: -10.28% | SUE: -0.73 | # QB: 0
Revenue Correlation: -3.29 | Revenue CAGR: -0.06% | SUE: 0.71 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=2.08 | Chg30d=+3.72% | Revisions=+50% | GrowthEPS=+27.3% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=2.38 | Chg30d=+4.89% | Revisions=+50% | GrowthEPS=+14.2% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +67% (up=6, down=0)